IM Cannabis Corp. IMCC PHARMA
Company Overview
IM Cannabis Corp. engages in importation, distribution and sale of medical cannabis products in Israel and Germany. It provides medical cannabis dried flowers; and full-spectrum cannabis extracts under the IMC, BLKMT, and LOT420 brands. The company serves medical patients. IM Cannabis Corp. was founded in 2008 and is headquartered in Vancouver, Canada.
Recent Developments
- Dec 2025 Revenue of $54.73M (+1.3% YoY); net profit $-11.32M.
- Trailing 12 Months Year-on-year growth — revenue -40.2%.
- 5-Year Trend Long-term compounding — revenue CAGR 0.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 0.24% |
| 1 Year: | -40.20% |
Stock Price Performance
| 1 Year: | -23.74% |
| 6 Months: | -91.88% |
| 3 Months: | -77.93% |
| 1 Month: | -47.73% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)27.35 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 97.3% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | IMCC IM Cannabis Corp. PHARMA | 1.96 | -0.03 | $1.18M | 0.00% | - | - | 0.24% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 12.50M | 12.70M | 13.85M | 15.68M | 8.68M |
| Cost of Revenue | - | 9.05M | 9.27M | 11.12M | 15.60M | 7.26M |
| Gross Profit | - | 3.45M | 3.42M | 2.73M | 82.00K | 1.42M |
| Operating Expenses | - | 3.29M | 3.77M | 3.81M | 10.40M | 3.10M |
| Operating Income | - | 158.00K | -350.00K | -1.08M | -10.32M | -1.68M |
| EBITDA | - | 621.00K | 2.01M | -2.54M | -7.22M | -1.18M |
| Interest Expense | - | 12.00K | 1.76M | 682.00K | 122.00K | 832.00K |
| Pretax Income | - | 146.00K | -220.00K | -3.72M | -7.86M | -2.51M |
| Tax Provision | - | -29.00K | -26.00K | 141.00K | 6.00K | -41.00K |
| Net Income | - | 275.00K | -309.00K | -3.65M | -7.63M | -2.28M |
| Diluted EPS | - | 0.09 | -0.09 | -0.75 | - | -0.38 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 54.34M | 48.80M | 54.03M | 54.73M |
| Cost of Revenue | - | 45.17M | 38.96M | 45.58M | 45.05M |
| Gross Profit | - | 9.16M | 9.85M | 8.45M | 9.69M |
| Operating Expenses | - | 31.66M | 22.02M | 18.68M | 21.27M |
| Operating Income | - | -22.50M | -12.18M | -10.23M | -11.59M |
| EBITDA | - | -16.76M | -4.75M | -8.10M | -6.95M |
| Interest Expense | - | 1.97M | 1.71M | 2.51M | 2.76M |
| Pretax Income | - | -26.06M | -9.46M | -12.79M | -11.66M |
| Tax Provision | - | -1.14M | 771.00K | -1.02M | 92.00K |
| Net Income | - | -188.89M | -9.50M | -10.59M | -11.32M |
| Diluted EPS | - | -161.88 | -4.25 | -4.51 | -2.67 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 60.68M | 48.81M | 39.19M | 31.74M |
| Current Assets | - | 32.67M | 24.27M | 23.36M | 22.74M |
| Cash & Equivalents | - | 2.45M | 1.81M | 863.00K | 2.73M |
| Inventory | - | 16.59M | 9.98M | 3.21M | 4.27M |
| Receivables | - | 8.68M | 7.65M | 13.80M | 10.85M |
| Total Liabilities | - | 36.88M | 35.11M | 36.04M | 35.35M |
| Current Liabilities | - | 33.82M | 32.85M | 34.92M | 34.01M |
| Long Term Debt | - | 399.00K | 394.00K | 466.00K | 936.00K |
| Total Debt | - | 11.53M | 13.78M | 18.01M | 16.27M |
| Total Equity | - | 22.65M | 14.47M | 5.24M | -858.00K |
| Shares Outstanding | - | 1.26M | 2.23M | 3.09M | 5.89M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -12.64M | -8.07M | -1.08M | 4.72M |
| Investing Cash Flow | - | -1.53M | -1.18M | -470.00K | -531.00K |
| Financing Cash Flow | - | 4.76M | 9.42M | 3.83M | 1.15M |
| Capital Expenditure | - | -1.56M | -581.00K | -156.00K | -13.00K |
| Free Cash Flow | - | -14.20M | -8.66M | -1.23M | 4.70M |
| Net Change in Cash | - | -9.41M | 160.00K | 2.28M | 5.33M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 16.9% | 20.2% | 15.6% | 17.7% |
| Operating Margin % | - | -41.4% | -24.9% | -18.9% | -21.2% |
| Net Margin % | - | -347.6% | -19.5% | -19.6% | -20.7% |
| ROE % | - | -833.9% | -65.6% | -201.9% | 1,319.2% |
| ROCE % | - | -83.8% | -76.3% | -239.7% | 510.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | HRT Financial LP | 1.22% | 7.34K | $31.07K |
| 2 | Citadel Advisors Llc | 0.28% | 1.69K | $7.14K |
| 3 | Jane Street Group, LLC | 0.21% | 1.26K | $5.34K |
| 4 | Stonex Group Inc. | 0.13% | 774 | $3.27K |
| 5 | Hidden Cove Wealth Management, LLC | 0.08% | 476 | $2.01K |
| 6 | Bank of Montreal /CAN/ | 0.07% | 404 | $1.71K |
| 7 | Federation Des Caisses Desjardins Du Quebec | 0.01% | 63 | $266 |
| 8 | National Bank of Canada/FI/ | - | 3 | $12 |
| 9 | Royal Bank of Canada | - | 2 | $8 |
| 10 | Osaic Holdings Inc. | - | 1 | $4 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for IMCC
A medical cannabis company raises $225,000 in a note that cannot be repaid in cash - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxPRHhjMU1wUDY5cUtMZVhoekkxeFFSNU9ZQXppc2FOdUVETDF2MUU2SUZkMXpHY0EtN25DcjdEV1l5bG93czVNTGRjSW5VYU9FTVQyUGxKSm1yMGJnUlc4Y1Y0b1ZZa2FFbXJTdUppWmpWcndWSmNuQnJhQVRseFpWUkowbmtfWVhzR0lUVz…
IM Cannabis Corp. (IMCC) Stock Falls on Q2 2026 Earnings - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxQUUJLNHFseFlySEVaQjJmUEE0YWphdS1OV2dzME1IbmJvb284bG5YZ0FHM29KbWs1bDZKenRhLUl4YzhGUjNKdFBCdUN2NWdQT1Q4bkNVX0Uwa3NJWGRFX0ZHS2cxcjc3OXlGVEdEVWU0S0RLdnE1WjV1eU5aYWtJcXdmTkx0RHNlR1Zob2…
IMCC - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE5weEQ5X3FWSVE1LVRSMWlaTUVCRG8ydV95ZnNJeENxdlRNOUN0MUk0X2k5VkRaNGJTdklGc1ZWQ1FWNDFoMmc?oc=5" target="_blank">IMCC</a> <font color="#6f6f6f">Finviz</font>…
IM Cannabis Announces Intention to Complete 30:1 Share Consolidation to Support Nasdaq Minimum Bid Price Compliance - PR Newswire
<a href="https://news.google.com/rss/articles/CBMi_wFBVV95cUxQaTc3allsTkdldGRmOHc5UDVmc01rUzVPUjRMWXF2SW5ULVl2ZFF6Q2dELS1SaTFkQmtfOUcxQnJEczVqd0ZEdXNzOGlncklPTVROY3FIRloxUzhPSU9rSTRnRDNPQ0g1MkFXdFJhUFcxTTQ5Um9XUHZHeURpT1ZkamxtNzhBbVZJUWUxTV…
IM Cannabis Agrees European Asset Sale as Transaction Targets C$3 Million Equity Improvement - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxOcGpIbm0zSjBUSG1scTBod2V2N0xpR3hSWWJ5SzdHdjNLWElEMUtFT2g1M2JZVEdrVTc1ZXQwTHdUempPZVZ4OS1fN21sRkRhbGZSRlJqQU1laG03WGpINlloakU3UUdfQzdzTm9oU3BmLWpyVTNSVWd3d2VndnBET0I2SFptb1NldVVqZE…
Enterprise value to EBIT forward of IM Cannabis Corp. – NASDAQ:IMCC - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxOcm5tSzZIS0ZEQ1JOaFRxTDNCbUhhc3RrOUZYX0ZRQmN1ZnlrUGtnZzFSYXlwRGQzQU44QU5aOHJfUjNzRmVGVEtrZWZTeVgxdElVcUxTWXI0RGZ0SHJwVUw3Zm9wWFBDN0ZMdXRnMHJxcVI0Njk5S18yQnVjdklrWWJWQ0RmYS1FYUhXND…
IMCC — Frequently Asked Questions
What is the current share price of IM Cannabis Corp. (IMCC)?
As of 2026-09-19 21:16 PDT, IM Cannabis Corp. (IMCC) trades at $1.96 on NasdaqCM. Its 52-week range is $1.96 to $73.20.
What is the market capitalisation of IMCC?
IM Cannabis Corp. (IMCC) has a market capitalisation of $1.18M on NasdaqCM.
What is the P/E ratio of IMCC?
IMCC trades at a trailing price-to-earnings (P/E) ratio of -0.03. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -0.57.
Is IMCC a good stock to buy?
This page provides a data-driven analysis of IM Cannabis Corp. (IMCC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.